Everhart Financial Group Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Everhart Financial Group Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 59.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 352 shares of the biopharmaceutical company’s stock after selling 508 shares during the quarter. Everhart Financial Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $251,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. Fairfield Financial Advisors LTD purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $37,000. Private Wealth Management Group LLC lifted its stake in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares in the last quarter. Finally, Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $673.60 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The stock has a 50-day moving average price of $706.92 and a two-hundred day moving average price of $894.87. The company has a market cap of $74.02 billion, a PE ratio of 17.60, a price-to-earnings-growth ratio of 2.38 and a beta of 0.08. The company has a current ratio of 4.73, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.67 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on REGN. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Evercore ISI reduced their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. TD Cowen dropped their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.